TITLE

The effect of interferon beta-1a on spasticity in primary progressive multiple sclerosis

AUTHOR(S)
Leary S M; Thompson A J
PUB. DATE
March 2004
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Mar2004, Vol. 75 Issue 3, p508
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
12653784

 

Related Articles

  • Treatment of Secondary Progressive Multiple Sclerosis: Current Recommendations and Future Prospects. Rice, G.P.A. // BioDrugs;1999, Vol. 12 Issue 4, p267 

    Disease progression and advancing disability will supervene in the majority of multiple sclerosis patients who are followed over the long-term. This process can begin insidiously from the onset of the disease (primary progression) or after one or more clinical flares (secondary progression). The...

  • Population based cost utility study of interferon beta-lb in secondary progressive multiple... Forbes, Raeburn B.; Lees, Ann // BMJ: British Medical Journal (International Edition);12/11/99, Vol. 319 Issue 7224, p1529 

    Presents a study which evaluated the cost utility of interferon beta-1b in secondary progressive multiple sclerosis. Comparison of the effect of treating people with secondary progressive multiple sclerosis with interferon beta against practice without interferon beta; Results of the study;...

  • Cannabinoids Control Tremor and Spasticity in Experimental Multiple Sclerosis. Baker, David; Pryce, Gareth; Croxford, J. Ludovic; Brown, Peter; Pertwee, Roger G.; Makriyannis, Alex; Layward, Lorna; Di Marzo, Vincenzo // Multiple Sclerosis (13524585);Dec2000, Vol. 6 Issue 6, p412 

    Investigates the effectiveness and mechanisms of cannabinoids in alleviating spasticity and tremor in an experimental multiple sclerosis. How cannabinoids exerts its effects; Effect of augmentation in endocannabinoid levels on spasticity.

  • A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Montalban, X.; Sastre-Garriga, J.; Tintoré, M.; Brieva, L.; Aymerich, F. X.; Río, J.; Porcel, J.; Borràs, C.; Nos, C.; Rovira, À. // Multiple Sclerosis (13524585);Oct2009, Vol. 15 Issue 10, p1195 

    Inflammation and neurodegeneration may have differential impacts on disease evolution in the different forms of multiple sclerosis. However, a beneficial effect of immunomodulatory drugs should not be ruled out in primary progressive multiple sclerosis. Our aim is to investigate the safety and...

  • Botox and MS.  // Inside MS;Jan-Mar2004, Vol. 22 Issue 1, p31 

    Presents information on the use of Botox to treat multiple sclerosis-related spasticity and bladder dysfunction. Background on spasticity; Effects of Botox on spasticity; Results of a study on the effects of Botox injections on bladder dysfunction and urinary urgency.

  • "Neutralizing" Neutralizing Antibodies. de Myer, Desiree // BioPharm International;Jun2003, Vol. 16 Issue 6, p8 

    Discusses the effects of neutralizing antibodies on clinical efficacy of interferon betas which are used as effective therapies for multiple sclerosis. Relapse rate; Increase in disability progression; Multiple factors that can cause the development of antibodies.

  • Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon β in relapsing -- remitting Multiple Sclerosis (ASIIMS) trial. Gonsette, Richard E.; Sindic5, Christian; D'hooghe, Marie B.; De Deyn, Peter-Paul; Medaer, Robert; Michotte, Alex; Seeldrayers, Pierrette; Guillaume, Daniel // Multiple Sclerosis (13524585);Apr2010, Vol. 16 Issue 4, p455 

    Anti-inflammatory drugs are effective on relapses, but neuroprotective agents to prevent disability are still unavailable. Uric acid has neuroprotective effects in experimental models including encephalomyelitis and appears to be involved in multiple sclerosis. Oral administration of inosine, a...

  • Late breaking news -- Oral presentations.  // Multiple Sclerosis (13524585);Nov2007, Vol. 13 Issue 9, pS268 

    The article presents abstracts of medical research which include whole-genome scan in primary progressive multiple sclerosis, high dose intravenous interferon beta (IFNb) therapy in patients with neutralizing antibodies, and comparative trial of inteferon beta-1a and glatiramer acetate in...

  • Therapy — immunomodulation — Part I.  // Multiple Sclerosis (13524585);Sep2005 Supplement, Vol. 11, p75 

    Discusses abstracts of studies about immunomodulation and multiple sclerosis, published in the October 2005 issue of the periodical "Multiple Sclerosis". "Prevention of Chronic Black Holes With Interferon Beta-1a in Secondary Progressive MS," by A. Traboulsee and colleagues; "Design and...

  • Muscle rupture caused by exacerbated spasticity in a patient with multiple sclerosis. Patejdl, Robert; Winkelmann, Alexander; Benecke, Reiner; Zettl, Uwe // Journal of Neurology;Dec2008 Supplement 6, Vol. 255, p115 

    We report a case of muscle rupture caused by acute exacerbation of spasticity in a patient with primary chronic progressive multiple sclerosis (PPMS). A complete disruption of the adductor muscles was diagnosed by sonography and still reproducible in a follow-up three months after the clinical...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics